The NIH model funds the process of making pluripotent stem cell lines and bears the cost. The process and the lines generated using this process can then be used by nonacademic entities without any restrictions from the NIH. This reduces the cost of development, and because a common process may be used by some of the entities, standardization and comparison of results are feasible. Abbreviations: CCRM, Colorado Center for Reproductive Medicine; cGMP, current Good Manufacturing Practice; ESC, embryonic stem cell; iPSC, induced pluripotent stem cell; PACT, Production Assistance for Cellular Therapies; PSC, pluripotent stem cell.